Navigation Menu

Clinical Trial External Search

Children (age < 18 years)
Adults (age >= 18 years)

Researcher Profile

Researcher Display

Patrick Chi-Chung Ma, MD, MSc

Patrick Chi-Chung Ma, MD, MSc

Professor, Department of Medicine
Interim Chief, Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies

Research Interests

  • Therapeutics
  • Neoplasms
  • Non-Small Cell Lung Carcinoma
  • Lung Neoplasms
  • Mutation
  • Small Cell Lung Carcinoma
  • ErbB Receptors
  • Hepatocyte Growth Factor
  • Neoplasm Metastasis
  • Protein-Tyrosine Kinases
  • Adenocarcinoma of Lung
  • Erlotinib Hydrochloride

Clinical Trials

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
NRG-LU008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial

Recent Publications


Guo, T, Zhao, S, Wang, P, Xue, X, Zhang, Y, Yang, M, Li, N, Li, Z, Xu, L, Jiang, L, Zhao, L, Ma, PC, Rosell, R, Li, J & Gu, C 2023, 'Erratum: YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma (Oncotarget (2017) 8 (48110-48125) DOI: 10.18632/oncotarget.18262)', Oncotarget, vol. 14, no. 1, pp. 280.


Kim, SY, Yin, J, Bohlman, S, Walker, P, Dacic, S, Kim, C, Khan, H, Liu, SV, Ma, PC, Nagasaka, M, Reckamp, KL, Abraham, J, Uprety, D, Wang, F, Xiu, J, Zhang, J, Cheng, H & Halmos, B 2022, 'Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing', JTO Clinical and Research Reports, vol. 3, no. 9, 100381.
Esposito, R, Polidori, T, Meise, DF, Pulido-Quetglas, C, Chouvardas, P, Forster, S, Schaerer, P, Kobel, A, Schlatter, J, Kerkhof, E, Roemmele, M, Rice, ES, Zhu, L, Lanzós, A, Guillen-Ramirez, HA, Basile, G, Carrozzo, I, Vancura, A, Ullrich, S, Andrades, A, Harvey, D, Medina, PP, Ma, PC, Haefliger, S, Wang, X, Martinez, I, Ochsenbein, AF, Riether, C & Johnson, R 2022, 'Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities', Cell Genomics, vol. 2, no. 9, 100171.
Shen, C, Holguin, RAP, Schaefer, E, Zhou, S, Belani, CP, Ma, PC & Reed, MF 2022, 'Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma', BMC health services research, vol. 22, no. 1, 470.


Mattes, MD, Eubank, TD, Almubarak, M, Wen, S, Marano, GD, Jacobson, GM & Ma, PC 2021, 'A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer', Clinical Lung Cancer, vol. 22, no. 4, pp. 268-273.
Ma, PC 2021, 'ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)', Precision Cancer Medicine, vol. 4, no. March, 6.
Khan, SA, Sun, Z, Dahlberg, S, Malhotra, J, Keresztes, R, Ikpeazu, C, Ma, P, Ramalingam, SS & Pillai, R 2021, 'Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)', JTO Clinical and Research Reports, vol. 2, no. 5, 100166.
He, Y, Chen, L, Zhao, L, Dang, S, Liu, G, Sasada, S, Ma, PC, Zandwijk, NV, Rosell, R, Popper, HH, Wang, H, Jiang, M, Guo, H, Liu, X, Chen, S, Zhang, X, Xu, M, Zhu, B, Liu, M & Zhou, C 2021, 'Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC', Theranostics, vol. 11, no. 14, pp. 7092-7109.
Albandar, HJ, Fuqua, J, Albandar, JM, Safi, S, Merrill, SA & Ma, PC 2021, 'Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: To rechallenge or not?', Cancers, vol. 13, no. 5, 989, pp. 1-15.
Nagasaka, M, Asad, MFB, Al Hallak, MN, Uddin, MH, Sukari, A, Baca, Y, Xiu, J, Magee, D, Mamdani, H, Uprety, D, Kim, C, Xia, B, Liu, SV, Nieva, JJ, Lopes, G, Bepler, G, Borghaei, H, Demeure, MJ, Raez, LE, Ma, PC, Puri, S, Korn, WM & Azmi, AS 2021, 'Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)', Lung Cancer, vol. 160, pp. 92-98.
Lee, M, Jain, P, Wang, F, Ma, PC, Borczuk, A & Halmos, B 2021, 'MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies', Expert Opinion on Therapeutic Targets, vol. 25, no. 4, pp. 249-268.


Attia, CG, Fei, N, Almubarak, M, Ma, PC & Mattes, MD 2020, 'Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer', Journal of Medical Imaging and Radiation Oncology, vol. 64, no. 6, pp. 866-872.
Brownmiller, T, Juric, JA, Ivey, AD, Harvey, BM, Westemeier, ES, Winters, MT, Stevens, AM, Stanley, AN, Hayes, KE, Sprowls, SA, Gatesman Ammer, AS, Walker, M, Bey, EA, Wu, X, Lim, ZF, Zhu, L, Wen, S, Hu, G, Ma, PC & Martinez, I 2020, 'Y chromosome LncRNA are involved in radiation response of male non-small cell lung cancer cells', Cancer Research, vol. 80, no. 19, pp. 4046-4057.